Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial
Key Points
Key points are not available for this paper at this time.
Abstract
UK Research and Innovation and UK Department of Health and Social Care.
Like
Bookmark
Share
View Full Paper
Like
Bookmark
Share
View Full Paper
Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial | Synapse